Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) — Cash Flow Quality Index
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a Cash Flow Quality Index of 4.85x as of September 2025. Operating cash flow of CN¥11.57 Million exceeds net income of CN¥2.39 Million, indicating high earnings quality where cash backs reported profits. Also explore 301211 current and non-current assets for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Cash Flow Quality Index (2017–2025)
Historical Cash Flow Quality Index for Hubei Biocause Heilen Pharmaceutical Co. Ltd. across 9 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Hubei Biocause Heilen Pharmaceutical Co. tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2025)
Year-by-year earnings quality comparison for Hubei Biocause Heilen Pharmaceutical Co. Ltd.. For live market cap and the full company financial profile, see how much is Hubei Biocause Heilen Pharmaceutical Co. worth.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.22x | CN¥7.55 Million | CN¥34.91 Million | ▼ -79.4% |
| 2024 | 1.05x | CN¥96.07 Million | CN¥91.55 Million | ▲ +34.8% |
| 2023 | 0.78x | CN¥137.06 Million | CN¥176.12 Million | ▼ -61.0% |
| 2022 | 1.99x | CN¥250.79 Million | CN¥125.72 Million | ▲ +95.7% |
| 2021 | 1.02x | CN¥123.98 Million | CN¥121.65 Million | ▲ +40.8% |
| 2020 | 0.72x | CN¥121.67 Million | CN¥168.07 Million | ▼ -64.1% |
| 2019 | 2.02x | CN¥372.33 Million | CN¥184.62 Million | ▲ +142.2% |
| 2018 | 0.83x | CN¥76.18 Million | CN¥91.48 Million | ▲ +130.3% |
| 2017 | -2.75x | CN¥-65.44 Million | CN¥23.77 Million | — |